Product pipeline

Redefining Precision Medicine

Our IT-ACTS Pipeline showcases a diverse range of high-impact therapies designed to address critical unmet needs.

irq

scb

sd

Our active programs are moving through discovery, IND-enabling, and early clinical stages to bring transformative treatments to all patients.

SOLID TUMORS

Our IT-ACTS pipeline for solid tumors, featuring programs like PH102 (GPC3, hepatocellular carcinoma), PH106 (pan-cancer), PH201 (gastrointestinal tumors), and PH206 (pan-cancer), is actively progressing through discovery and early clinical development.

PH102

Target: GPC3

Platform: IT-ACTS/Autologous

Study Population/Indication: Hepatocellular carcinoma

Current Stage: IND-enabling

PH106

Target: Proprietary

Platform: IT-ACTS/Autologous

Study Population/Indication: Pan-cancer

Current Stage: Discovery

PH201

Target: Proprietary

Platform: IT-ACTS/Allogeneic

Study Population/Indication: Gastrointestinal tumors

Current Stage: Discovery

PH202

Target: Proprietary

Platform: IT-ACTS/Autologous

Study Population/Indication: Pan-cancer

Current Stage: Discovery

FIBROTIC DISEASE

Our product pipeline includes promising programs like PH105 for liver cirrhosis and PH301 for muscle fibrosis, both advancing through discovery and early clinical stages.

PH105

Target: Proprietary

Platform: IT-ACTS/Autologous

Study Population/Indication: Liver cirrhosis

Current Stage: Discovery

PH301

Target: Proprietary

Platform: IT-ACTS/Allogeneic

Study Population/Indication: Muscle Fibrosis

Current Stage: Discovery

The Power Behind Our Pipeline: The IT-ACTS Advantage

IT-ACTS: The Living Drug Platform

This highly adaptable platform can be customized with various molecules to meet diverse clinical needs across a wide range of indications.

Unlocking Broad Potential & Patient Safety

IT-ACTS offers remarkable versatility, deployable in both autologous and allogeneic settings, prioritizing patient safety by minimizing side effects. This broad clinical potential allows it to effectively treat diverse diseases, overcome resistance, and amplify combination therapies without compromising safety.